The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
BAL: An excess proportion of eosinophils
Publications
Mitropoulou G, Daccord C, Sauty A, Pasche A, Egger B, Aedo Lopez V, Letovanec I, Beigelman-Aubry C, Nicod LP, Lazor R
Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
Respiration; international review of thoracic diseases 2020 Jan 08;;1-6 — 2020 Jan 08 — 1-6
Jodai T, Yoshida C, Sato R, Kakiuchi Y, Sato N, Iyama S, Kimura T, Saruwatari K, Saeki S, Ichiyasu H, Fujii K, Tomita Y
A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.
Immunity, inflammation and disease 2019 03;7;3-6 — 2019 03 — 3-6
Ishiwata T, Ebata T, Iwasawa S, Matsushima J, Ota S, Nakatani Y, Tsushima K, Tada Y, Tatsumi K, Takiguchi Y
Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP).
Internal medicine (Tokyo, Japan) 2017 Sep 01;56;2311-2315 — 2017 Sep 01 — 2311-2315